

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4446057

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MARK BERNINGER	04/25/2017
PUTHUPPARAMPIL SCARIA	04/26/2017
MARTIN WOODLE	05/25/2017
RECEIVING PARTY DATA	
Name:	APARNA BIOSCIENCES CORPORATION (ALSO KNOWN AS APARNA BIOSCIENCES AND ALSO KNOWN AS APARNA BIOSCIENCES CORP.)
Street Address:	12111 PARKLAWN DRIVE
Internal Address:	SUITE 125
City:	ROCKVILLE
State/Country:	MARYLAND
Postal Code:	20852-1707
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	60995238
Application Number:	12680548
Application Number:	14754239
CORRESPONDENCE DATA	
Fax Number:	(206)359-8000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	206-359-7198
Email:	patentprocurement@perkinscoie.com
Correspondent Name:	PERKINS COIE LLP
Address Line 1:	P.O. BOX 1247
Address Line 2:	PATENT PROCUREMENT
Address Line 4:	SEATTLE, WASHINGTON 98111-1247
ATTORNEY DOCKET NUMBER:	000966-8003.US01
NAME OF SUBMITTER:	TRICIA WILLIAMS
SIGNATURE:	/Tricia Williams/
DATE SIGNED:	06/06/2017

Total Attachments: 4

source=000966-8003_assignment#page1.tif

source=000966-8003_assignment#page2.tif

source=000966-8003_assignment#page3.tif

source=000966-8003_assignment#page4.tif

ASSIGNMENT BY INVENTORS


This Assignment is by **Mark BERNINGER** residing at 1033 Main Street, Gaithersburg, Maryland 20878; **Puthupparampil SCARIA** residing at 9602 Swallow Point Way, Montgomery Village, Maryland 20886; and **Martin WOODLE** residing at 8205 Beech Tree Road, Bethesda, Maryland 20817 (hereinafter referred to collectively as "ASSIGNORS" and individually as "ASSIGNOR") have invented one or more certain inventions described in U.S. Patent Application No. 12/680,548 filed October 6, 2010, which is a national stage application of International Patent Application No. PCT/US08/78021 filed September 26, 2008, which claims the benefit of U.S. Provisional Patent Application No. 60/995,238 filed September 25, 2007. Each of the above-referenced patent applications is entitled "**Therapeutic and Vaccine Polyelectrolyte Nanoparticle Compositions.**"

Aparna Biosciences Corporation (also known as Aparna Biosciences and also known as Aparna Biosciences Corp.), a corporation of Maryland having its principal place of business at 12111 Parklawn Drive, Suite 125, Rockville, Maryland 20852-1707 ("ASSIGNEE"), desires to affirm its ownership of the entire right, title and interest in and to the Invention(s) and the Application, and in and to any patents (collectively, "Patents") that may be granted for the Invention(s) in the United States or in any foreign countries.

For valuable consideration, the receipt and sufficiency of which each ASSIGNOR acknowledges, each ASSIGNOR affirms they sold, assigned, and transferred to ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in and to: the Invention(s), the Application, and any Patents; any divisions, continuations, and continuations-in-part of the Application, and any other application claiming priority rights from the Application; any reissues, reexaminations, or extensions of any and all Patents; the right to file foreign applications directly in the name of ASSIGNEE; and the right to claim priority rights deriving from the Application (collectively, the "Rights"). Each ASSIGNOR affirms that they conveyed their rights in the invention to ASSIGNEE at the time the invention was made by virtue of their employment/engagement with ASSIGNEE. Each ASSIGNOR agrees to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as ASSIGNEE deems necessary or

desirable to: perfect ASSIGNEE's enjoyment of the Rights; conduct proceedings regarding the Rights, including any litigation or interference proceedings; or perfect or defend title to the Rights. ASSIGNORS request the Commissioner of Patents to issue any Patent of the United States that may be issued on the Invention(s) to ASSIGNEE. This Assignment may be executed in counterparts.

— ASSIGNORS —

Date: April 25, 2017 Signature: 
Mark Berninger


Date: _____ Signature: _____
Puthupparampil Scaria

Date: _____ Signature: _____
Martin Woodle

— ASSIGNEE —

On behalf of Aparna Biosciences Corporation

:


Signature

Martin Woodle
Printed Name

MAY 25, 2017
Date

CEO Aparna Biosciences

ASSIGNMENT BY INVENTORS

This Assignment is by **Mark BERNINGER** residing at 1033 Main Street, Gaithersburg, Maryland 20878; **Puthupparampil SCARIA** residing at 9602 Swallow Point Way, Montgomery Village, Maryland 20886; and **Martin WOODLE** residing at 8205 Beech Tree Road, Bethesda, Maryland 20817 (hereinafter referred to collectively as “ASSIGNORS” and individually as “ASSIGNOR”) have invented one or more certain inventions described in U.S. Patent Application No. 12/680,548 filed October 6, 2010, which is a national stage application of International Patent Application No. PCT/US08/78021 filed September 26, 2008, which claims the benefit of U.S. Provisional Patent Application No. 60/995,238 filed September 25, 2007. Each of the above-referenced patent applications is entitled “**Therapeutic and Vaccine Polyelectrolyte Nanoparticle Compositions.**”

Aparna Biosciences Corporation (also known as Aparna Biosciences and also known as Aparna Biosciences Corp.), a corporation of Maryland having its principal place of business at 12111 Parklawn Drive, Suite 125, Rockville, Maryland 20852-1707 (“ASSIGNEE”), desires to affirm its ownership of the entire right, title and interest in and to the Invention(s) and the Application, and in and to any patents (collectively, “Patents”) that may be granted for the Invention(s) in the United States or in any foreign countries.

For valuable consideration, the receipt and sufficiency of which each ASSIGNOR acknowledges, each ASSIGNOR affirms they sold, assigned, and transferred to ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in and to: the Invention(s), the Application, and any Patents; any divisions, continuations, and continuations-in-part of the Application, and any other application claiming priority rights from the Application; any reissues, reexaminations, or extensions of any and all Patents; the right to file foreign applications directly in the name of ASSIGNEE; and the right to claim priority rights deriving from the Application (collectively, the “Rights”). Each ASSIGNOR affirms that they conveyed their rights in the invention to ASSIGNEE at the time the invention was made by virtue of their employment/engagement with ASSIGNEE. Each ASSIGNOR agrees to not sign any writing or do any act conflicting with this assignment, and, without further compensation, sign all documents and do such additional acts as ASSIGNEE deems necessary or

desirable to: perfect ASSIGNEE's enjoyment of the Rights; conduct proceedings regarding the Rights, including any litigation or interference proceedings; or perfect or defend title to the Rights. ASSIGNORS request the Commissioner of Patents to issue any Patent of the United States that may be issued on the Invention(s) to ASSIGNEE. This Assignment may be executed in counterparts.

— ASSIGNORS —

Date: _____ Signature: _____
Mark Berninger

Date: April 26, 2017 Signature: _____
Puthupparampil Scaria

Date: MAY 25, 2017 Signature: _____
Martin Woodle

— ASSIGNEE —

On behalf of Aparna Biosciences Corporation

:

Signature

MARTIN WOODLE
Printed Name

MAY 25, 2017
Date

CEO APARNA BIOSCIENCES